These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10589745)

  • 21. Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
    Fidias P; Pennell NA; Boral AL; Shapiro GI; Skarin AT; Eder JP; Kwoh TJ; Geary RS; Johnson BE; Lynch TJ; Supko JG
    J Thorac Oncol; 2009 Sep; 4(9):1156-62. PubMed ID: 19704336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
    Rao S; Watkins D; Cunningham D; Dunlop D; Johnson P; Selby P; Hancock BW; Fegan C; Culligan D; Schey S; Morris TC; Lissitchkov T; Oliver JW; Holmlund JT
    Ann Oncol; 2004 Sep; 15(9):1413-8. PubMed ID: 15319248
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).
    Oza AM; Elit L; Swenerton K; Faught W; Ghatage P; Carey M; McIntosh L; Dorr A; Holmlund JT; Eisenhauer E;
    Gynecol Oncol; 2003 Apr; 89(1):129-33. PubMed ID: 12694666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
    Morris MJ; Tong WP; Cordon-Cardo C; Drobnjak M; Kelly WK; Slovin SF; Terry KL; Siedlecki K; Swanson P; Rafi M; DiPaola RS; Rosen N; Scher HI
    Clin Cancer Res; 2002 Mar; 8(3):679-83. PubMed ID: 11895895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression.
    McKay RA; Miraglia LJ; Cummins LL; Owens SR; Sasmor H; Dean NM
    J Biol Chem; 1999 Jan; 274(3):1715-22. PubMed ID: 9880552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.
    Dean NM; McKay R
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11762-6. PubMed ID: 7972137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alpha.
    Dennis JU; Dean NM; Bennett CF; Griffith JW; Lang CM; Welch DR
    Cancer Lett; 1998 Jun; 128(1):65-70. PubMed ID: 9652794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intravenous infusion in patients with advanced carcinoma.
    Cunningham CC; Holmlund JT; Geary RS; Kwoh TJ; Dorr A; Johnston JF; Monia B; Nemunaitis J
    Cancer; 2001 Sep; 92(5):1265-71. PubMed ID: 11571742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302).
    Glover JM; Leeds JM; Mant TG; Amin D; Kisner DL; Zuckerman JE; Geary RS; Levin AA; Shanahan WR
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1173-80. PubMed ID: 9316823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks.
    Davis AJ; Gelmon KA; Siu LL; Moore MJ; Britten CD; Mistry N; Klamut H; D'Aloisio S; MacLean M; Wainman N; Ayers D; Firby P; Besterman JM; Reid GK; Eisenhauer EA
    Invest New Drugs; 2003 Feb; 21(1):85-97. PubMed ID: 12795533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced activity of an antisense oligonucleotide targeting murine protein kinase C-alpha by the incorporation of 2'-O-propyl modifications.
    McKay RA; Cummins LL; Graham MJ; Lesnik EA; Owens SR; Winniman M; Dean NM
    Nucleic Acids Res; 1996 Feb; 24(3):411-7. PubMed ID: 8602351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.
    Yazaki T; Ahmad S; Chahlavi A; Zylber-Katz E; Dean NM; Rabkin SD; Martuza RL; Glazer RI
    Mol Pharmacol; 1996 Aug; 50(2):236-42. PubMed ID: 8700129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas.
    Grossman SA; Alavi JB; Supko JG; Carson KA; Priet R; Dorr FA; Grundy JS; Holmlund JT
    Neuro Oncol; 2005 Jan; 7(1):32-40. PubMed ID: 15701280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in CD-1 mice.
    Henry SP; Taylor J; Midgley L; Levin AA; Kornbrust DJ
    Antisense Nucleic Acid Drug Dev; 1997 Oct; 7(5):473-81. PubMed ID: 9361906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A; Huang CH; Rudin CM; Marshall J; Collins B; Dul JL; Zhang C; Kumar D; Gokhale PC; Ahmad A; Ahmad I; Sherman JW; Kasid UN
    Clin Cancer Res; 2006 Feb; 12(4):1251-9. PubMed ID: 16489081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense knockdown of PKC-alpha using LNA-oligos.
    Hansen JB; Westergaard M; Thrue CA; Giwercman B; Oerum H
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):1607-9. PubMed ID: 14565477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.